We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration.
- Authors
Winkler, Anne; Wrzos, Claudia; Haberl, Michael; Weil, Marie-Theres; Ming Gao; Möbius, Wiebke; Odoardi, Francesca; Thal, Dietmar R.; Chang, Mayland; Opdenakker, Ghislain; Bennett, Jeffrey L.; Nessler, Stefan; Stadelmann, Christine; Gao, Ming
- Abstract
Approximately 80% of neuromyelitis optica spectrum disorder (NMOSD) patients harbor serum anti-aquaporin-4 autoantibodies targeting astrocytes in the CNS. Crucial for NMOSD lesion initiation is disruption of the blood-brain barrier (BBB), which allows the entrance of Abs and serum complement into the CNS and which is a target for new NMOSD therapies. Astrocytes have important functions in BBB maintenance; however, the influence of their loss and the role of immune cell infiltration on BBB permeability in NMOSD have not yet been investigated. Using an experimental model of targeted NMOSD lesions in rats, we demonstrate that astrocyte destruction coincides with a transient disruption of the BBB and a selective loss of occludin from tight junctions. It is noteworthy that BBB integrity is reestablished before astrocytes repopulate. Rather than persistent astrocyte loss, polymorphonuclear leukocytes (PMNs) are the main mediators of BBB disruption, and their depletion preserves BBB integrity and prevents astrocyte loss. Inhibition of PMN chemoattraction, activation, and proteolytic function reduces lesion size. In summary, our data support a crucial role for PMNs in BBB disruption and NMOSD lesion development, rendering their recruitment and activation promising therapeutic targets.
- Subjects
NEUROMYELITIS optica; BLOOD-brain barrier; TIGHT junctions; ASTROCYTES; AUTOANTIBODIES; BIOLOGICAL models; RESEARCH; MONONUCLEAR leukocytes; ANIMAL experimentation; RESEARCH methodology; MEDICAL cooperation; EVALUATION research; RATS; COMPARATIVE studies; CELLS
- Publication
Journal of Clinical Investigation, 2021, Vol 131, Issue 5, p1
- ISSN
0021-9738
- Publication type
journal article
- DOI
10.1172/JCI141694